PET分子成像用于帕金森病伴左旋多巴诱导异动症研究进展  

Research progresses of PET molecular imaging for Parkinsondisease complicated with levodopa-induced dyskinesia

作　　者：李霜 宋天彬[1,3] 杨畅 王静娟 张春 卢洁 LI Shuang;SONG Tianbin;YANG Chang;WANG Jingjuan;ZHANG Chun;LU Jie(Department of Radiology and Nuclear Medicine,Xuanwu Hospital,Capital Medical University,Beijing 100053,China;Department of Nuclear Medicine,Xiangyang No.1 People's Hospital Affiliated to Hubei University of Medicine,Xiangyang 441000,China;Beijing Key Laboratory of Magnetic Resonance Imaging Brain and Brain Informatics,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院放射与核医学科,北京100053 [2]湖北医药学院附属襄阳市第一人民医院核医学科,湖北襄阳441000 [3]磁共振成像脑信息学北京市重点实验室,北京100053

出　　处：《中国医学影像技术》2024年第5期774-778,共5页Chinese Journal of Medical Imaging Technology

基　　金：国家重点研发计划(2022YFC2406900)。

摘　　要：左旋多巴是治疗帕金森病(PD)的标准方法;但随疾病进展和长期治疗,可产生左旋多巴诱导的异动症(LID),极大降低患者生活质量。PET脑分子成像可活体检测显像剂在分子水平的摄取分布情况,从而反映PD伴LID患者脑功能及代谢,有助于临床早诊断及早治疗。本文就PET分子成像用于PD伴LID的研究进展进行综述。Levodopa is the standard therapy for Parkinson disease(PD),however,with the progression of the disease and long-term treatment,levodopa-induced dyskinesia(LID)can occur,greatly reducing the quality of patients'life.PET brain molecular imaging can detect the uptake and distribution of imaging agents at the molecular level in vivo,thereby reflecting the brain function and metabolism of patients with PD complicated with LID,which is helpful for early clinical diagnosis and treatment.The research progresses of PET molecular imaging for PD complicated with LID were reviewed in this article.

关 键 词：帕金森病 脑 左旋多巴 正电子发射断层显像 

分 类 号：R742[医药卫生—神经病学与精神病学] R817.4[医药卫生—临床医学]